 Axovant Gene Therapies Ltd. AXGT, a clinical-stage company developing innovative gene therapies for neurological diseases, today announced recent progress in its gene therapy programs, including a 12-month update on its Parkinsons program. At 12 months post-dosing, patients in the first dose cohort 4.2 x 106 TU demonstrated an average 22-point change from baseline in motor function as assessed by the UPDRS Part III OFF score, which represents a 37 improvement. Previously, at 6 months post-dosing, these patients demonstrated an average 17-point change from baseline, or 29 improvement, on the same scale. 